According to a recent LinkedIn post from Xeltis, the company plans an intensive presence at multiple scientific and partnering conferences in Europe and Brazil in 2026. The post highlights ongoing engagement around its regenerative vascular access conduits, including lead candidate aXess, as the company moves toward potential commercialization.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The events listed include BIO Capital Europe in Amsterdam, several vascular and dialysis-focused meetings in Spain, the Netherlands, Italy, and Brazil, and broader health innovation and medtech forums in Utrecht and Lisbon. Senior leadership, including the CEO and CMO, are slated for presentations and panels, suggesting a coordinated effort to raise clinical and investor visibility.
For investors, this activity may indicate a late-stage development and partnering push intended to validate the aXess program, accelerate clinical adoption, and prepare market access pathways. Extensive conference participation could support future fundraising, strategic collaborations, or regional expansion if Xeltis can convert scientific interest into commercial agreements and regulatory progress.